@TheADDF
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure #Alzheimers.
New York, NY
Joined February 2009
- Tweets5.8K
- Following4.9K
- Followers18.4K
- Likes3.3K
On World Alzheimer’s Day, we recognize the urgency and extraordinary progress underway. The ADDF is investing in bold science and helping accelerate a future in which combination therapies and precision medicine define how we diagnose and ultimately treat Alzheimer’s.
Sex hormones like estrogen have long been studied for their role in women’s health, and researchers are continuing to uncover how hormonal changes across menopause may influence brain health. @LiveScience
livescience.com/health/alzhe…
Alzheimer's Drug Discovery Foundation retweeted
Less than two months to go until the @nycmarathon, which I’m running for @TheADDF.
I would love your support:
fundraisers.nyrr.org/ernest-…
Friends, I'm running the @NYCMarathon this fall for @TheADDF for the 12th time. I'd love your support as I run to help find better treatment and a cure for Alzheimer's! 🏃♂️🏃♂️🏃♂️ #TeamADDF
More info here: fundraisers.nyrr.org/ernest-…
We’re thrilled to introduce the ADDF’s new LinkedIn newsletter. Each issue will bring you exclusive insights from our scientists and leaders, along with the latest scientific advances, investment trends, and key developments shaping the field. bit.ly/4xQrZ96
The ADDF’s Aaron Burstein spoke with @Inc about LM11A-31, an experimental therapy from ADDF-funded PharmatrophiX that may protect synapses and reduce harmful changes linked to both tau and amyloid in Alzheimer’s.
inc.com/lucia-auerbach/alzhe…
The ADDF’s CEO, Isobel Coleman, has seen firsthand the extraordinary progress in Alzheimer’s research. She shares how the ADDF will carry that progress forward through scientific expertise, strategic investment, and collaboration. bit.ly/4ghOsV0
The FDA clearance of @C2NDiagnostics' PrecivityAD2 blood test marks another major milestone in the rapid shift toward more accessible and scalable Alzheimer’s diagnostics, moving Alzheimer’s care closer to precision medicine.
bit.ly/45zLp5I
The ADDF's CEO, Isobel Coleman, shares her vision for the ADDF’s next chapter, driving greater impact across Alzheimer’s research while building on its scientific legacy and catalyzing progress in drug development, biomarkers, and prevention.
bit.ly/4ghOsV0
Researchers say the oral drug LM11A-31 slowed the decline of brain-network function in a small trial, pointing to a potential broader strategy for treating Alzheimer’s. trib.al/uFQbyYo
Tau research is gaining momentum as the field looks beyond amyloid. In @AARP, the ADDF's Interim Chief Science Officer Laura Nisenbaum explains why tau is closely tied to cognitive decline and why it remains an important target in Alzheimer’s. aarp.org/health/conditions-t…
Alzheimer's Drug Discovery Foundation retweeted
Patients with early #Alzheimers disease experienced slower cognitive decline and greater reductions in #tau with #diranersen compared with placebo, researchers from @biogen said at #AAIC26. Also, @TheADDF comments.
@alzassociation
vist.ly/5di8n
For 25 years, the ADDF has supported the work of Dr. Frank Longo, including an early investment in PharmatrophiX. That long-term support is reflected in the continued progress of LM11A-31, which Dr. Longo recently discussed on @CNBC's Squawk Box.
cnbc.com/video/2026/07/27/al…
Alzheimer's Drug Discovery Foundation retweeted
“Subcutaneous approval is an important step toward the kind of scalable care model #Alzheimers will need as the field moves from single-drug treatment toward combination therapies,” said Dr. Laura Nisenbaum of @TheADDF.
#lecanemab #leqembi
vist.ly/5bnzw
New phase 2 data presented by @Biogen today at #AAIC2026 show diranersen (#BIIB080) is the first tau-targeting drug to demonstrate a robust biomarker effect and clinical signal.
Read more: bit.ly/4gxy6cF
The ADDF’s Diagnostics Accelerator and @MichaelJFoxOrg are joining forces to accelerate the development of scalable, minimally invasive biomarkers for co-pathologies found across Alzheimer’s and Parkinson’s.
Learn more: bit.ly/4h7EmYL
Alzheimer's Drug Discovery Foundation retweeted
“#Alzheimer’s is not driven by a single mechanism. It involves amyloid, tau, and novel pathways like #inflammation, vascular health and metabolism,” Dr. Laura Nisenbaum of @TheADDF said about what she expects to see at #AAIC26.
@alzassociation
vist.ly/5ax75
New in Solving Alzheimer's: the ADDF's Laura Nisenbaum explores how Alzheimer's diagnosis is evolving. From FDA-cleared blood tests to AI-powered tools, these innovations are making detection more accessible, scalable, and precise.
bit.ly/4p1rB3V
Alzheimer's Drug Discovery Foundation retweeted
Friends, I'm running the @NYCMarathon this fall for @TheADDF for the 12th time. I'd love your support as I run to help find better treatment and a cure for Alzheimer's! 🏃♂️🏃♂️🏃♂️ #TeamADDF
More info here: fundraisers.nyrr.org/ernest-…
Could AI detect Alzheimer's through speech?
Changes in word choice and speech patterns can emerge years before symptoms appear. A new paper in Alzheimer's & Dementia explores how AI could turn these signals into digital markers for cognitive decline.
bit.ly/4vlZdvJ
Today, the ADDF announced that Co-Founder and Chief Science Officer Dr. Howard Fillit will retire and transition to an emeritus role. Please join us in recognizing Dr. Fillit’s extraordinary contributions to the ADDF and the Alzheimer’s field.
bit.ly/4eu6LoT
